 ASLAN Pharmaceuticals Limited Nasdaq:ASLN, TPEx:6497, a clinical-stage immunology and oncology focused biopharmaceutical company, today announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, is scheduled to present an overview of the company on Wednesday, 26 February 2020 at 09:00am EST. An archived version of the presentation will be available in the Investors section of ASLANs website at following the event. 